Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 5, 2023
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 171,400...
-
Jun 28, 2023
Phase 3 Study is Supported by Previously Presented Phase 1 Study Results, Including a 78.6% SVR35 and 58.3% TSS50 in Intent to Treat Patients at Week 24 at the 60mg Dose NEWTON, Mass., June 28, 2023 /
-
Jun 1, 2023
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 44,600 restricted...
-
Jun 1, 2023
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate...
-
May 23, 2023
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have...